Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation

Recombinant factor VIIa (rFVIIa, NovoSeven) has been registered for the treatment of bleeding episodes in patients with inherited or acquired hemophilia A or B with inhibitors. Furthermore, rFVIIa has been used successfully for the treatment of bleeding in patients with thrombocytopenia, and acquire...

Full description

Saved in:
Bibliographic Details
Published in:Intensive care medicine 2004-06, Vol.30 (6), p.1232-1234
Main Authors: GIELEN-WIJFFELS, S. E. M. J, VAN MOOK, W. N. K. A, VAN DER GEEST, S, RAMSAY, G
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Factor VIIa - therapeutic use
Humans
Intensive care medicine
Kidney Transplantation
Male
Medical sciences
Middle Aged
Postoperative Hemorrhage - drug therapy
Recombinant Proteins - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recombinant factor VIIa (rFVIIa, NovoSeven) has been registered for the treatment of bleeding episodes in patients with inherited or acquired hemophilia A or B with inhibitors. Furthermore, rFVIIa has been used successfully for the treatment of bleeding in patients with thrombocytopenia, and acquired and congenital platelet dysfunction. The definite spectrum of indications for rFVIIa has not yet been established. We describe a case of severe intra-abdominal bleeding 3 days after non-heart beating kidney transplantation in a patient with severe coronary artery disease in which rFVIIa (a single intravenous bolus injection 70 microg/kg bodyweight) was successfully used. No thrombotic complications occurred. This report demonstrates that rFVIIa might be safe and effective after recent renal transplantation.
ISSN:0342-4642
1432-1238
DOI:10.1007/s00134-004-2181-0